7月 2026
- 首頁
- Syros Pharmaceuticals
7月 2026Syros Pharmaceuticals的市場佔有率分析
Syros Pharmaceuticals(包含公司地區)
查看更多網站流量與參與度資訊- syros.com
Syros Pharmaceuticals截至 7月 2026 的總收入為 15M - 25M
Syros Pharmaceuticals 熱門網域產生的總收入
Syros Pharmaceuticals 熱門網域 3 年內的總收入
Syros Pharmaceuticals 熱門網域的總收入
Syros Pharmaceuticals的熱門網域總造訪量
了解Syros Pharmaceuticals市場觸達率與潛在市場影響力。
過去 3 個月的訪問總量
無可顯示數據
無可顯示數據
Syros Pharmaceuticals的熱門網域平均造訪時長
分析Syros Pharmaceuticals參與度指標。
過去 3 個月平均造訪時長
無可顯示數據
無可顯示數據
Syros Pharmaceuticals的熱門網域平均頁面瀏覽量
了解Syros Pharmaceuticals如何保持使用者的參與度、培養其興趣,並鼓勵他們採取下一步。
過去 3 個月平均頁面瀏覽量
無可顯示數據
無可顯示數據
想要取得更深入的流量洞見?
篩選超過 2,030 萬家線上企業。在流量激增、開始或停止使用技術或獲得正面評價時,發現新的潛在客戶。
新聞與訊號來自Syros Pharmaceuticals
透過 Similarweb 銷售訊號提醒,每當目標受眾出現新的機會或威脅時,你就會收到每日更新的已識別購買訊號。
新聞Syros Pharmaceuticals partnered with Oxford Finance LLC on Feb 28th '25.In response to these issues, Syros Pharmaceuticals has secured a forbearance agreement with Oxford Finance after defaulting on a loan, with a resolution aimed for by the end of February 2025.
1月 29, 2025閱讀更多
新聞Syros Pharmaceuticals has issues with violations of the securities laws.LOS ANGELES-(BUSINESS WIRE)-The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ: SYRS) for violations of the securities laws.
8月 21, 2024閱讀更多
新聞Syros Pharmaceuticals hired Nancy Simonian as CEO on Dec 2nd '23.Also today, Syros announced the retirement as Chief Executive Officer (CEO) of Nancy Simonian, M.D., and the appointment of Conley Chee, Syros' Chief Commercial Officer (CCO) and Chief Business Officer (CBO), as CEO, effective December 2, 2023.
10月 1, 2023閱讀更多
查看所有Syros Pharmaceuticals信號
讓銷售團隊專注於最有希望的機會。透過安排機會的優先順序,並在正確的時間參與,您可將工作最佳化,並完成更多交易。
